Journal of International Psychiatry

Objective: to analyze and compare the clinical effects of clozapine and chlorpromazine on maintaining cognitive function and alexithymia in schizophrenia. Methods: 102 schizophrenics were observed in this study, which were included from December 2018 to December 2019. According to the method of computer random grouping, the subjects of observation were divided into routine group and research group. 51 cases in each group. The routine group was given chlorpromazine maintenance treatment, while the study group was given clozapine maintenance treatment. In addition, 51 healthy people in the same period were selected as the normal group. The cognitive function and alexithymia of the three groups were compared, and the incidence of adverse reactions of two different drugs was observed. Results: the cognitive function score of the study group and the routine group was lower than that of the normal group (P < 0.05), but there was no difference between the study group and the routine group (P > 0.05); the alexithymia score of the study group and the routine group was higher than that of the normal group (P < 0.05), but there was no difference between the study group and the routine group (P > 0.05); the adverse drug reaction of the study group was less than that of the routine group (P < 0.05). Conclusion: in the clinical treatment of schizophrenic patients, whether chlorpromazine or clozapine maintenance treatment, there are still some cognitive and alexithymia disorders. In terms of drug safety, clozapine has some advantages. It is suggested that the rational choice of drug treatment should be based on the actual condition of patients.

clozapine; chlorpromazine; schizophrenia; cognitive function; alexithymia